The U.S. Food and Drug Administration said on Monday it had approved Vertex Pharmaceuticals Inc’s three-drug combination for cystic fibrosis (CF), a rare genetic condition. The approval comes months ahead of the FDA’s previously announced action date in March, sending the drugmaker’s shares up 4.1% at $183.53 in late afternoon trading, before being halted for news pending. The treatment, Trikafta, is a combination of three drugs that target a defective protein responsible for the life-threatening disease that causes the build up of thick mucus in body parts such as the lungs and digestive tract. …read more
Source:: Yahoo Finance
